This randomized, double-masked, double-dummy, parallel-group, multicenter trial enrolled 360 patients with moderate-to-severe recurrent major depression. Patients were treated with bupropion SR 150 to 400 mg/d, sertraline 50 to 200 mg/d, or placebo for up to 8 weeks. Patients' depression and ...
Interventions Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering. Main Outcomes and Measures The primary end point was the time to development of a major adverse cardiovascular event (MACE: cardiovascular death,...
Healthy subjects (n = 22) received a single oral dose of bupropion 150 mg alone (study period 1) and on day 12 of a 16ヾay regimen of upadacitinib 30 mg once daily (study period 2). Serial blood samples for measurement of bupropion and hydroxybupropion plasma concentrations were ...
Intervention Varenicline titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or placebo (n = 341) for 12 weeks, plus weekly brief smoking cessation counseling. Main Outcome Measures Continuous abstinence from smoking during the last 4 weeks of...
Methods: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks. Results: CAR9–12 was greater for varenicline (44.0%) versus bupropion SR (29.7...
Later, a phase 3 study was conducted comparing DEX-BUP 45 mg/105 mg with placebo in patients with moderate-to-severe MDD. Similarly, MADRS and CGI-S scores were significantly reduced in the treatment group. Adverse effects were similar in all groups.Therapeutic Advance:Clinical response to ...
Intervention Patients were allocated to 9 weeks of either sustained release bupropion, 150 mg/day for days 1 to 3 and 300 mg/day for days 4 to 63 (n=244); nicotine patch, 21 mg/day for weeks 2 to 7, 14 mg/day for week 8, and 7 mg/day for week 9 (n=244); or bupropion ...
Bupropion hydrochloride (extended release-XL) 150 mg/day was initiated to the patient. The leukocyte count of her treatment was 3890/pl at the third month and 3730/pl at the fourth month. The leukocyte count was at normal value before initiation of bupropion hydrochloride (7220/pl) and after...
Case We report the case of a patient with schizoaffective disorder who developed two psychotic episodes respectively after a four and a two-day administration of sustained-release (SR) bupropion at a dose of 150聽mg/day. To our knowledge, this is the first reported case of involuntary ...
METHODS: Six hundred twenty-nine subjects with CVD who smoked >/=10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary efficacy endpoint: continuous abstinence from ...